Because paradoxical increase in thrombin activity was reported after the administration of streptokinase in patients with acute myocardial infarction the velocity of reperfusion and degree of myocardial damage were studied when heparin was infused during rather than after streptokinase infusion. Thirty seven consecutive patients with acute myocardial infarction were randomised to receive intravenous heparin during (group 1, n = 18) or after (group 2, n = 19) streptokinase (1P5 megaunits over 60 minutes). Markers of reperfusion were monitored every 15 minutes for 3 hours. The serum concentration of creatine kinase was measured every 2 hours. The two groups were similar in terms of age and sex distribution, infarct site, time to treatment, and baseline myocardial ischaemia. Patients in group 1 had a significantly shorter mean (SD) reperfusion time (57 (35) minutes v 101 (47)). From 60 to 120 minutes after randomisation there were significant differences in ST segment elevation between the groups. Serum creatine kinase MB peaked earlier (8 (2) hours) in group 1 than in group 2 (10 (4) hours). The peak concentration was significantly lower in group 1 (87 (47) mU/ml) than in group 2 (134 (96) mUIml) and infarcts were smaller (25 2 (9-8) gram equivalentslm2) in group 1 than in group 2 (35-1 (10-2) gram equivalents/m2).
Abstract
Because paradoxical increase in thrombin activity was reported after the administration of streptokinase in patients with acute myocardial infarction the velocity of reperfusion and degree of myocardial damage were studied when heparin was infused during rather than after streptokinase infusion. Thirty seven consecutive patients with acute myocardial infarction were randomised to receive intravenous heparin during (group 1, n = 18) or after (group 2, n = 19) streptokinase (1P5 megaunits over 60 minutes). Markers of reperfusion were monitored every 15 TREATMENT PROTOCOL All patients received an intravenous infusion of streptokinase (1 5 megaunits over 1 h). Each patient was randomly assigned to receive either a simultaneous infusion of heparin (aiming at an activated partial thromboplastin time of 2-0 to 2-5 times normal) (group 1) or saline (group 2). At the end of streptokinase infusion group 2 patients were given heparin (according to the same protocol as group 1). Intravenous heparin was continued for 4-5 days provided that there was no serious bleeding. Subsequently patients were placed on an antiplatelet regimen consisting of aspirin (400 mg per day) and dipyridamole (75 mg three times per day). During the first 24-48 h patients were also given intravenous glyceryl trinitrate to unload the heart and reduce coronary vasomotility. '3 Other medications were prescribed in accordance with the individual's clinical condition. wave. The sum of scores for all leads provided an index of myocardial ischaemia. Patients were asked to grade the intensity of chest pain from 0 to 100 on a visual analogue scale. Then the 12 lead electrocardiograms and the intensity of chest pain were monitored every 15 min for 3 hours and also whenever there was a change in symptoms, ST segment shift on the monitor, or in cardiac rhythm. Blood samples were drawn to measure serum creatine kinase MB every second hour during the first 16 hours and then every fourth hour for the next 24 hours. Then serum creatine kinase MB was measured once daily until it became normal.
To speed up the initial treatment we chose to recognise reperfusion non-invasively. Figure 2 shows the time course of ST segment elevation. In most patients there were no statistically significant differences between the two groups up to 45 minutes after randomisation. At 60 minutes group 1 patients showed a significantly lower ST segment elevation (p < 0-05). The difference remained significant up to 120 minutes.
The time to peak creatine kinase MB was 8 (2) h in group 1 and 10 (4) h in group 2 (p < 0-05). On average the peak concentration of creatine kinase MB was 87 (47) mU/ml in group 1 and 134 (96) mU/ml in group 2 (p < 0 05). The infarct was significantly smaller in group 1 (25.2 (9 8) g equivalents/m2) than in group 2 (35-1 (10-2) g equivalents/m2) (p < 0-05).
Many patients developed skin haematomas. Three patients (16-6%) in group 1 and six (31-5%) in group 2 had major bleeding comBaseline characteristics ofpatients in study groups Our study shows that when heparin treatment is given there is a clear advantage in infusing it with rather than after streptokinase. This conclusion is supported by the quicker resolution of electrocardiographic signs of ischaemia and by the earlier peaking of serum concentrations of creatine kinase MB. These signs of faster reperfusion5 18 were associated with a significantly lower peak value of serum creatine kinase and a smaller infarct. Earlier studies by our group in which serum creatine kinase MB was measured frequently showed a good correlation between left ventricular function and both enzymatically assessed infarct size and the extension of resting thallium-201 perfusion defects (measured by single-photon emission tomography).24
The reduction of infarct size that we saw in the present study when heparin was given early was the result of a mean reduction of 44 minutes in the time to reperfusion. These data confirm that the human heart is very sensitive to the duration of ischaemia before reperfusion and support the concept that reperfusion strategies should also take account of the speed of reperfusion.
